In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
Dynogen's GI, GU Products To Benefit From $50M Round (BioWorld Today)
Dynogen's GI, GU Products To Benefit From $50M Round (BioWorld Today)
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
